CA2156287C - Indolin-2-one derivative - Google Patents

Indolin-2-one derivative Download PDF

Info

Publication number
CA2156287C
CA2156287C CA002156287A CA2156287A CA2156287C CA 2156287 C CA2156287 C CA 2156287C CA 002156287 A CA002156287 A CA 002156287A CA 2156287 A CA2156287 A CA 2156287A CA 2156287 C CA2156287 C CA 2156287C
Authority
CA
Canada
Prior art keywords
group
substituted
unsubstituted
indolin
ureido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002156287A
Other languages
English (en)
French (fr)
Other versions
CA2156287A1 (en
Inventor
Toru Esaki
Takashi Emura
Eiichi Hoshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CA2156287A1 publication Critical patent/CA2156287A1/en
Application granted granted Critical
Publication of CA2156287C publication Critical patent/CA2156287C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CA002156287A 1993-02-17 1994-02-17 Indolin-2-one derivative Expired - Fee Related CA2156287C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP6729793 1993-02-17
JP5/67297 1993-02-17
JP5/167262 1993-05-31
JP16726293 1993-05-31
PCT/JP1994/000235 WO1994019322A1 (en) 1993-02-17 1994-02-17 Indolin-2-one derivative

Publications (2)

Publication Number Publication Date
CA2156287A1 CA2156287A1 (en) 1994-09-01
CA2156287C true CA2156287C (en) 2005-12-27

Family

ID=26408486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002156287A Expired - Fee Related CA2156287C (en) 1993-02-17 1994-02-17 Indolin-2-one derivative

Country Status (19)

Country Link
US (5) US5952511A (US06559137-20030506-C00039.png)
EP (1) EP0685463B1 (US06559137-20030506-C00039.png)
JP (1) JP3419539B2 (US06559137-20030506-C00039.png)
KR (1) KR100226310B1 (US06559137-20030506-C00039.png)
CN (1) CN1046268C (US06559137-20030506-C00039.png)
AT (1) ATE217864T1 (US06559137-20030506-C00039.png)
AU (1) AU6044894A (US06559137-20030506-C00039.png)
CA (1) CA2156287C (US06559137-20030506-C00039.png)
CZ (1) CZ290504B6 (US06559137-20030506-C00039.png)
DE (1) DE69430664T2 (US06559137-20030506-C00039.png)
ES (1) ES2176236T3 (US06559137-20030506-C00039.png)
FI (1) FI112652B (US06559137-20030506-C00039.png)
HU (1) HUT74105A (US06559137-20030506-C00039.png)
MY (1) MY128102A (US06559137-20030506-C00039.png)
NO (1) NO305201B1 (US06559137-20030506-C00039.png)
PL (1) PL176710B1 (US06559137-20030506-C00039.png)
RU (1) RU2128170C1 (US06559137-20030506-C00039.png)
TW (1) TW281669B (US06559137-20030506-C00039.png)
WO (1) WO1994019322A1 (US06559137-20030506-C00039.png)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
CN1069314C (zh) * 1993-11-26 2001-08-08 田边制药株式会社 2-氧代二氢吲哚衍生物
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
WO1997033867A1 (fr) * 1996-03-11 1997-09-18 Ube Industries, Ltd. Procede de preparation de composes d'indole actifs sur le plan optique
AU3459497A (en) * 1996-07-12 1998-02-09 Chugai Seiyaku Kabushiki Kaisha Cancer cell proliferation inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
ATE285396T1 (de) 1998-06-19 2005-01-15 Vertex Pharma Sulfonamide als aspartyl-protease-inhibitoren
WO2000033834A1 (en) * 1998-12-04 2000-06-15 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP4058243B2 (ja) 1999-01-29 2008-03-05 中外製薬株式会社 軟骨形成促進剤およびインドリン−2−オン誘導体
ATE425142T1 (de) * 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
DK1233958T3 (da) * 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
WO2001066142A1 (fr) * 2000-03-10 2001-09-13 Chugai Seiyaku Kabushiki Kaisha Preparations pour chondrogenese
US7612065B2 (en) 2000-04-21 2009-11-03 Vertex Pharmaceuticals Incorporated Inhibitors of c-JUN N-terminal kinases (JNK)
WO2001098269A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2413418A1 (en) * 2000-06-21 2001-12-27 Joseph B. Santella Piperidine amides as modulators of chemokine receptor activity
JP4897221B2 (ja) 2002-12-20 2012-03-14 チバ ホールディング インコーポレーテッド アミン類の合成及びその合成のための中間体
CN1324009C (zh) * 2003-01-30 2007-07-04 普文英 化合物1-n-甲氧基-2-氧-吲哚-3-乙酰胺及其药物用途
US20080030974A1 (en) * 2006-08-02 2008-02-07 Abu-Ageel Nayef M LED-Based Illumination System
US20090050905A1 (en) * 2007-08-20 2009-02-26 Abu-Ageel Nayef M Highly Efficient Light-Emitting Diode
WO2010090862A2 (en) * 2009-01-21 2010-08-12 Abu-Ageel Nayef M Illumination system utilizing wavelength conversion materials and light recycling
US8987310B2 (en) 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CN102516153B (zh) * 2011-12-14 2014-03-12 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
BR112016011727A2 (pt) 2013-11-22 2017-08-08 CL BioSciences LLC Antagonistas de gastrina para o tratamento e prevenção de osteoporose
KR102161674B1 (ko) * 2014-02-18 2020-10-05 주식회사 대웅제약 이사틴 유도체 및 이의 제조방법
CN113456631B (zh) * 2021-08-06 2022-06-21 徐州医科大学 一种靶向acsl1的小分子药物及其在治疗子宫内膜癌中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
JPS62228072A (ja) * 1985-12-20 1987-10-06 Kissei Pharmaceut Co Ltd 3−アミノインドリン−2−オン誘導体
JPS62234080A (ja) * 1985-12-20 1987-10-14 Kissei Pharmaceut Co Ltd インドリン−2−オン誘導体
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
JPS62270576A (ja) * 1986-05-19 1987-11-24 Kissei Pharmaceut Co Ltd イサチン誘導体
JPS63156771A (ja) * 1986-12-19 1988-06-29 Kissei Pharmaceut Co Ltd 3−アミノインドリン−2−オン誘導体
JPS62156771A (ja) * 1986-12-19 1987-07-11 Tokyo Shokai:Kk 処方箋処理装置
US4876259A (en) * 1987-01-05 1989-10-24 E. I. Du Pont De Nemours And Company 3,3-disubstituted indolines
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
WO1992004038A1 (en) * 1990-08-31 1992-03-19 Warner-Lambert Company Pro-drugs for cck antagonists
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
CA2055094A1 (en) * 1990-11-13 1992-05-14 Mark G. Bock Cholecystokinin antagonist
JPH05104510A (ja) * 1991-10-18 1993-04-27 Inax Corp 基板へのモルタル塗布方法

Also Published As

Publication number Publication date
CZ290504B6 (cs) 2002-08-14
CN1046268C (zh) 1999-11-10
PL176710B1 (pl) 1999-07-30
NO953235L (no) 1995-10-09
KR960701011A (ko) 1996-02-24
CN1117727A (zh) 1996-02-28
FI953866A (fi) 1995-08-16
AU6044894A (en) 1994-09-14
FI112652B (fi) 2003-12-31
US6114536A (en) 2000-09-05
ATE217864T1 (de) 2002-06-15
CZ209695A3 (en) 1995-12-13
FI953866A0 (fi) 1995-08-16
EP0685463B1 (en) 2002-05-22
HU9502415D0 (en) 1996-05-28
EP0685463A4 (US06559137-20030506-C00039.png) 1996-01-03
US6207836B1 (en) 2001-03-27
MY128102A (en) 2007-01-31
NO953235D0 (no) 1995-08-17
JP3419539B2 (ja) 2003-06-23
PL310168A1 (en) 1995-11-27
US5952511A (en) 1999-09-14
CA2156287A1 (en) 1994-09-01
HUT74105A (en) 1996-11-28
DE69430664T2 (de) 2003-01-30
NO305201B1 (no) 1999-04-19
RU2128170C1 (ru) 1999-03-27
WO1994019322A1 (en) 1994-09-01
ES2176236T3 (es) 2002-12-01
US6127544A (en) 2000-10-03
TW281669B (US06559137-20030506-C00039.png) 1996-07-21
JPH0748349A (ja) 1995-02-21
US6031111A (en) 2000-02-29
KR100226310B1 (ko) 1999-10-15
DE69430664D1 (de) 2002-06-27
EP0685463A1 (en) 1995-12-06

Similar Documents

Publication Publication Date Title
CA2156287C (en) Indolin-2-one derivative
US5594022A (en) Tachykinin antagonists
US7544708B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
EA009051B1 (ru) О-замещенные гидроксиарильные производные
WO2007095495A2 (en) Benzodiazepine gcnf modulators for stem cell modulation
HUT54643A (en) Process for producing 2-aminoarylindoles and indolines, as well as pharmaceutical compositions comprising same
JPH10501803A (ja) チアゾリジン誘導体、それらの製造及びそれらを含有する薬物
EP0775118A1 (en) Benzimidazole derivatives having dopaminergic activity
JPH04211652A (ja) ヘキサヒドロベンズ[cd]インドール
CA2173693A1 (en) 4-indolylpiperazinyl derivatives
KR870001019B1 (ko) 치환된 1-피리딜옥시-3-인돌일알킬아미노-2-프로판올의 제조방법
AU675654B2 (en) Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors
SK5172003A3 (en) Triazole derivatives and pharmaceutical compositions comprising them
JPH11255743A (ja) 光学活性のインドール誘導体の製造方法及びその製造中間体
WO1991011444A1 (fr) Compose de piperazine, sa production et son utilisation en medecine
GB2162523A (en) Intermediates for syntheses of indole derivatives
JPH08208643A (ja) 6−メトキシ−1h−ベンゾトリアゾール−5−カルボキサミド誘導体及びそれを含有する医薬組成物
JPH0399078A (ja) Nf―1616―904物質の製造法
CA2121609A1 (en) Tricyclic quinoxalinedione derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed